- Home
- MFIN vs GALT Comparison
MFIN vs GALT Comparison
Compare MFIN & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- GALT
- Stock Information
- Founded
- MFIN 1995
- GALT 2000
- Country
- MFIN United States
- GALT United States
- Employees
- MFIN N/A
- GALT N/A
- Industry
- MFIN Finance: Consumer Services
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- MFIN Finance
- GALT Health Care
- Exchange
- MFIN Nasdaq
- GALT Nasdaq
- Market Cap
- MFIN 223.8M
- GALT 232.3M
- IPO Year
- MFIN 1996
- GALT N/A
- Fundamental
- Price
- MFIN $10.71
- GALT $4.60
- Analyst Decision
- MFIN Strong Buy
- GALT Strong Buy
- Analyst Count
- MFIN 1
- GALT 3
- Target Price
- MFIN $12.00
- GALT $6.00
- AVG Volume (30 Days)
- MFIN 42.9K
- GALT 241.8K
- Earning Date
- MFIN 10-28-2025
- GALT 08-14-2025
- Dividend Yield
- MFIN 4.48%
- GALT N/A
- EPS Growth
- MFIN N/A
- GALT N/A
- EPS
- MFIN 1.75
- GALT N/A
- Revenue
- MFIN $332,256,000.00
- GALT N/A
- Revenue This Year
- MFIN N/A
- GALT N/A
- Revenue Next Year
- MFIN $1.53
- GALT N/A
- P/E Ratio
- MFIN $6.12
- GALT N/A
- Revenue Growth
- MFIN 16.48
- GALT N/A
- 52 Week Low
- MFIN $7.40
- GALT $0.73
- 52 Week High
- MFIN $10.98
- GALT $4.71
- Technical
- Relative Strength Index (RSI)
- MFIN 60.53
- GALT 69.41
- Support Level
- MFIN $10.27
- GALT $3.93
- Resistance Level
- MFIN $10.73
- GALT $4.35
- Average True Range (ATR)
- MFIN 0.27
- GALT 0.27
- MACD
- MFIN 0.00
- GALT 0.03
- Stochastic Oscillator
- MFIN 80.95
- GALT 91.67
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.